Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298336 | 1.00 | ALDH1A1 (0.55) | ALDH1A1TP53PLK1MAPTMEN1 | |
| SCHEMBL4294360 | 1.00 | ALDH1A1 (0.55) | ALDH1A1TP53PLK1MAPTMEN1 | |
| SCHEMBL4294363 | 1.00 | ALDH1A1 (0.55) | ALDH1A1TP53PLK1MAPTMEN1 | |
| SCHEMBL4294365 | 1.00 | ALDH1A1 (0.55) | ALDH1A1TP53PLK1MAPTMEN1 | |
| SCHEMBL4298333 | 1.00 | ALDH1A1 (0.55) | ALDH1A1TP53PLK1MAPTMEN1 | |
| SCHEMBL4563958 | 0.80 | HDAC4 (0.55) | ALDH1A1TP53PLK1MAPTMEN1 | |
| SCHEMBL4564140 | 0.80 | HDAC4 (0.55) | ALDH1A1TP53PLK1MAPTMEN1 | |
| SCHEMBL4563957 | 0.80 | HDAC4 (0.55) | ALDH1A1TP53PLK1MAPTMEN1 | |
| SCHEMBL13611522 | 0.80 | HDAC4 (0.55) | ALDH1A1TP53PLK1MAPTMEN1 | |
| SCHEMBL13625100 | 0.80 | HDAC4 (0.55) | ALDH1A1TP53PLK1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286791-A1 | Amide Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| WO-2008011131-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286791-A1 | Amide Compounds | DLAT, DGAT2, DGAT1 | ALDH1A1 231/4885TP53 2704/4885PLK1 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.